Insight Molecular Diagnostics Inc. — Director's Dealing 2018

Jun 1, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2018-05-23

Reporting Person: ANNETT WILLIAM (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-05-23	Option to Purchase Common Stock	$2.35	A	180000	Acquired	2028-05-22	Common Stock (180000)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to Purchase Common Stock	$4.70	2027-02-16	Common Stock (225000)	250000	Direct
Option to Purchase Common Stock	$3.06	2026-02-15	Common Stock (250000)	250000	Direct
Option to Purchase Common Stock	$2.20	2025-06-15	Common Stock (605000)	605000	Direct
Option to Purchase Common Stock	$2.20	2025-01-08	Common Stock (5000)	5000	Direct

Footnotes

F1: One quarter of the options shall vest upon completion of the clinical utility study for OncoCyte's DetermaVu product candidate and OncoCyte has received a publication date for a full article describing those results, and the balance shall vest upon obtaining a Medicare local coverage determination for OncoCyte's DetermaVu product candidate.

F2: One quarter of the options vested on February 16, 2018, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment.

F3: One quarter of the options vested on February 15, 2017, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment.

F4: One quarter of the options vested on June 15, 2016, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment.

F5: Became exercisable in two equal installments based upon continued service on the board of directors from the date of grant on January 9, 2015.